Risk factor
Significant default risk
Profitability factor
Undervalued vs peers
About
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITDA, underpriced on P/FCF.
Target Price
The average target price of BION.SW is 53 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell